Current clinician practice for thyroid hormone regulation of patients is based upon guesswork and experience rather than quantified analysis, which exposes patients under longer risk and discomfort. To quantitatively analyze the thyroid regulation for patients of different thyroid states, we develop a two-dimensional mathematical model that can be applied to analyze the dynamic behaviors of thyroid hormones with or without drug intervention. The unified model can be employed to study the regulation of TSH (thyroid-stimulating hormone) and FT4 (free thyroxine) for euthyroid (normal thyroid) subjects, Hashimoto’s thyroiditis, and Graves’ disease patients, respectively. The results suggest that the level of TPOAb (thyroid peroxidase antibody) may be a factor determining whether the patient would progress from euthyroid state to subclinical or clinical hypothyroidism, and that increased TRAb (TSH receptor antibody) may lead Graves’ disease to deteriorate from the early stage to overt hyperthyroidism. Given the early blood-test data, we demonstrate the feasibility for healthcare professionals to apply our model in choosing an appropriate dosage regimen for patients to achieve the desired TSH and FT4 levels within a specified time frame. This proposed model has the potential to optimize personalized treatment and shorten the therapeutic time for patients suffering from Hashimoto’s thyroiditis and Graves’ disease.

目前临床医生对患者甲状腺激素调节的做法是基于猜测和经验，而不是量化分析，这会使患者面临更长的风险和不适。为了定量分析不同甲状腺状态患者的甲状腺调节，我们开发了一个二维数学模型，可用于分析有或没有药物干预的甲状腺激素的动态行为。统一模型可分别用于研究甲状腺功能正常（正常甲状腺）受试者、桥本甲状腺炎和格雷夫斯病患者的 TSH（促甲状腺激素）和 FT4（游离甲状腺素）的调节。结果表明，TPOAb（甲状腺过氧化物酶抗体）水平可能是决定患者是否会从甲状腺功能正常状态发展为亚临床或临床甲状腺功能减退症的一个因素，而 TRAb（TSH 受体抗体）的增加可能导致 Graves 病恶化。早期明显甲亢。鉴于早期的血液测试数据，我们证明了医疗保健专业人员应用我们的模型为患者选择合适的剂量方案以在指定时间范围内达到所需的 TSH 和 FT4 水平的可行性。这种提议的模型有可能优化个性化治疗并缩短桥本甲状腺炎和格雷夫斯病患者的治疗时间。并且增加的 TRAb（TSH 受体抗体）可能导致 Graves 病从早期恶化到明显的甲亢。鉴于早期的血液测试数据，我们证明了医疗保健专业人员应用我们的模型为患者选择合适的剂量方案以在指定的时间范围内达到所需的 TSH 和 FT4 水平的可行性。这种提议的模型有可能优化个性化治疗并缩短桥本甲状腺炎和格雷夫斯病患者的治疗时间。并且增加的 TRAb（TSH 受体抗体）可能导致 Graves 病从早期恶化到明显的甲亢。鉴于早期的血液测试数据，我们证明了医疗保健专业人员应用我们的模型为患者选择合适的剂量方案以在指定时间范围内达到所需的 TSH 和 FT4 水平的可行性。这种提议的模型有可能优化个性化治疗并缩短桥本甲状腺炎和格雷夫斯病患者的治疗时间。